Blue Note leukaemia DTx gets FDA breakthrough tag
pharmaphorum
JANUARY 11, 2022
A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA. BNT200 and BNT100 are among a series of therapies that Blue Note is developing for specific cancer settings.
62 
Let's personalize your content